secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001193125-22-051106
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q4 net loss $98.6M; FDA approved PYRUKYND for PK deficiency; cash $1.3B
-----------------------------------------------------------------------------

- Net loss $98.6M in Q4 2021 vs $84.5M in Q4 2020; full-year net loss $356.5M.
- Received FDA approval for PYRUKYND (mitapivat), first therapy for hemolytic anemia in adults with PK deficiency.
- Cash, cash equivalents and marketable securities $1.3B as of Dec. 31, 2021; expects to fund operations to cash-flow positivity.
- Dosed first patients in three pivotal trials of PYRUKYND in thalassemia and sickle cell disease.
- R&D expenses $73.3M in Q4 2021, up from $59.4M in Q4 2020 due to pivotal study start-up costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522051106/0001193125-22-051106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522051106/d252010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-051106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer